His infamous sketch in the back of a yellow cab became the most imitated logo in history—and cities are still copying it today. In the summer of 1977, New York City was burning. A 25-hour ...

C. diff causes nearly 30,000 deaths each year in the US, says Ferring, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections.

Months after enabling Deep Research in its expensive $200 ChatGPT Pro plan, OpenAI is now rolling out the feature to all users. Anyone can now access a lightweight version of Deep Research for ...

AI video generators are rapidly improving and becoming more widely available, with Google's Veo 2 now built into the Gemini app for anyone paying for a Google One AI Premium plan. Like OpenAI's ...

The US Food and Drug Administration (FDA) has approved Swiss drugmaker Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firedenovec-vncg) for the treatment of adult patients with high-risk ...

The FDA has approved a new, 12,000 square-foot drug product manufacturing facility for Adstiladrin, Ferring Pharmaceuticals’ branded form of intravesical non-replicating gene therapy (nadofaragene ...

What makes Coca-Cola so fascinating is its long-standing reputation and cultural significance. The brand's distinctive logo and cursive script have become synonymous with happiness, refreshment, and ...

Prior to joining NMS Labs, Kosheleva held senior roles at Ferring Pharmaceuticals, DST Global Solutions, OppenheimerFunds, and IBM. She is also Finance Chair for the Drug Information Association ...

While there has still been plenty going on Parliament this month, it has been a real pleasure to have a little more time to be out and about in Worthing West during the sunny Easter recess. Did you ...

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications. In a video ...

Stephen Brown brings you evening updates, conversation and great music.

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.